0 274

Cited 9 times in

Characterizing the outcomes of metastatic papillary renal cell carcinoma

 John Connor Wells  ;  Frede Donskov  ;  Anna P. Fraccon  ;  Felice Pasini  ;  Georg A. Bjarnason  ;  Benoit Beuselinck  ;  Jennifer J. Knox  ;  Sun Young Rha  ;  Neeraj Agarwal  ;  Isaac Alex Bowman  ;  Jae‐Lyun Lee  ;  Sumanta K. Pal  ;  Sandy Srinivas  ;  Douglas Scott Ernst  ;  Ulka N. Vaishampayan  ;  Lori A. Wood  ;  Robin Simpson  ;  Guillermo De Velasco  ;  Toni K. Choueiri  ;  Daniel Y. C. Heng 
 CANCER MEDICINE, Vol.6(5) : 902-909, 2017 
Journal Title
Issue Date
Antineoplastic Agents/therapeutic use* ; Carcinoma, Renal Cell/drug therapy* ; Carcinoma, Renal Cell/pathology ; Clinical Trials as Topic ; Disease-Free Survival ; Female ; Humans ; Kidney Neoplasms/drug therapy* ; Kidney Neoplasms/pathology ; Male ; Molecular Targeted Therapy/methods* ; Neoplasm Metastasis ; Prognosis ; Standard of Care ; Survival Analysis ; Treatment Outcome
Metastatic renal cell carcinoma ; outcomes ; papillary ; response rate ; survival ; targeted therapy
Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.